The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.96
Bid: 19.52
Ask: 19.96
Change: 0.16 (0.81%)
Spread: 0.44 (2.254%)
Open: 19.50
High: 19.96
Low: 19.30
Prev. Close: 19.80
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence Partner Update

25 Mar 2020 17:05

RNS Number : 6248H
Nanoco Group PLC
25 March 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

FOR IMMEDIATE RELEASE

 25 March 2020

NANOCO GROUP PLC

("Nanoco", the "Group", or the "Company")

 

Licence Partner Update

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, announces the following update on its licence agreement with Merck Gmbh ("Merck").

Merck have indicated their intention to negotiate a new supply and licensing agreement to replace the existing one which was signed on 29 July 2016. That licence was an evergreen agreement that renewed automatically every year and had escalating minimum annual royalties that were payable unless terminated. Merck have chosen to issue a three month notice of termination of the existing licence while renegotiations take place. Merck and Nanoco continue to work closely to find a mutually acceptable agreement.

During this time Merck continue to place additional purchase orders with Nanoco for small scale R&D services and CFQD product for display applications while the renegotiation takes place. The minimum annual licence fee of 0.5m for the contract year ending 30 June 2020 will still be payable and no previously forecast income or cash has been lost as a result of this decision by Merck.

The Company is continuing to review its strategic options including, but not limited to, a potential sale of the Company through a formal sale process as announced on 5 November and will make a further announcement in due course.

 

Michael Edelman, Chief Executive of Nanoco, said:

"We continue to work collaboratively with Merck and we had based our plans and forecasts on the risk of this renegotiation occurring. While we continue to actively engage with Merck to find a new basis for long term co-operation we will continue to supply them with paid for R&D services and CFQD product."

- Ends -

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Brian Tenner, Chief Financial Officer

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

MHP Communications

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com

Tel: +44 (0) 20 3128 8570

 

In accordance with Rule 26.1 of the City Code on Takeovers and Mergers, a copy of this announcement will, subject to certain restrictions relating to persons resident in restricted jurisdictions, be available at www.nanocotechnologies.com/investor-relations/. The person responsible for arranging for the release of this announcement on behalf of Nanoco is Brian Tenner, Chief Financial Officer. For the avoidance of doubt, the content of the website referred to above is not incorporated into and does not form part of this announcement.

 

This announcement is not an announcement of a firm intention to make an offer under Rule 2.7 of the Code and there can be no certainty that an offer will be made, nor as to the terms on which any offer might be made. Any offer (if made) will be made solely by certain offer documentation, which will contain the full terms and conditions of any offer (if made), including details of how such offer may be accepted. This announcement has been prepared in accordance with English law and the Code, and information disclosed may not be the same as that which would have been prepared in accordance with laws outside of the United Kingdom. The release, distribution or publication of this announcement in jurisdictions outside of the United Kingdom may be restricted by laws of the relevant jurisdictions, and therefore persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.

 

MAR

 

The information contained within this announcement is considered by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information will be considered to be in the public domain.

 

FORWARD LOOKING STATEMENTS

 

This announcement (including information incorporated by reference in this announcement), oral statements made regarding the formal sale process, and other information published by Nanoco may contain statements about Nanoco that are or may be deemed to be forward looking statements. Such statements are prospective in nature. All statements other than historical statements of facts may be forward looking statements. Without limitation, statements containing the words "targets", "plans", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "estimates", "projects" or "considers" or other similar words may be forward looking statements.

 

Forward looking statements inherently contain risks and uncertainties as they relate to events or circumstances in the future. Important factors such as business or economic cycles, the terms and conditions of Nanoco's financing arrangements, tax rates, or increased competition may cause Nanoco's actual financial results, performance or achievements to differ materially from any forward looking statements. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward looking statements, which speak only as of the date hereof. Nanoco disclaims any obligation to update any forward looking or other statements contained herein, except as required by applicable law.

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display and Electronics markets. One of the interesting properties of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAXDSAEFEEFA
Date   Source Headline
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
23rd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20244:06 pmRNSTR-1: Notification of Major Holdings
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20243:02 pmRNSExercise of Deferred Bonus Options
18th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
17th Apr 20241:56 pmRNSNotification of Major Holdings
17th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
16th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Apr 20244:10 pmRNSDirector/PDMR Shareholding
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSResult of Tender Offer
28th Mar 202412:52 pmRNSGeneral Meeting - Voting Results
27th Mar 20247:00 amRNSInterim Results
11th Mar 202412:47 pmRNSPosting of Circular
11th Mar 20247:00 amRNSProposed return of up to £33.0 million
8th Feb 20247:00 amRNSHalf Year Trading Update
7th Feb 202411:23 amRNSDirector Declaration
24th Jan 20247:00 amRNSReceipt of Final Litigation Proceeds
23rd Jan 20244:02 pmRNSNotification Of Transactions By PDMR
16th Jan 20243:40 pmRNSDirector/PDMR Shareholding
15th Jan 20244:35 pmRNSHolding(s) in Company
12th Jan 20249:45 amRNSJoint Development Agreement with European Customer
22nd Dec 20237:00 amRNSAppointment of Financial Adviser and Joint Broker
21st Dec 202312:00 pmRNSAppointments of Non-Executive Directors
12th Dec 20239:35 amRNSBlocklisting six-monthly return
7th Dec 20233:23 pmRNSResult of AGM
7th Dec 20237:00 amRNSAGM Statement & Trading Update
15th Nov 20237:00 amRNSFirst ever commercial production order
13th Nov 20234:28 pmRNS2023 Annual Report and Notice of AGM
7th Nov 20237:00 amRNSJoint Development Agreement with Asian Customer
2nd Nov 20232:18 pmRNSHolding(s) in Company
17th Oct 20237:00 amRNSUnaudited Preliminary Results
10th Oct 20237:00 amRNSNotice of Results
3rd Oct 20234:32 pmRNSForeign Currency Hedge of Litigation Settlement
14th Aug 20233:58 pmRNSResult of Meeting
8th Aug 20237:00 amRNSTrading Update
7th Aug 20237:00 amRNSGlass Lewis recommends to support Nanoco’s Board
2nd Aug 20237:00 amRNSHolding(s) in Company
2nd Aug 20237:00 amRNSISS recommendation to support Nanoco’s Board
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.